The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes
Primary result · mGFRResult — go to the resultDifference −7.9 mL/min 95% CI −11.1 to −4.7Authors' conclusion
Treatment with empagliflozin for 13 weeks reduced mGFR, estimated ECV and estimated PV in patients with T2D and high risk of cardiovascular events.
Study context
- Population
- Patients with T2D at high risk of cardiovascular eventsrandomized
- Participants
- 91 patients
- Comparison
- Empagliflozin 25 mg vs placebo once daily for 13 weeks
- Empagliflozinn = 45
- Placebon = 45reference
- Primary endpoint
- Between-group change in measured GFR (measured glomerular filtration rate (mGFR)) by the 51 Cr-EDTA method
- Follow-up
- 13 weeks
Methodological detailsrandomized, placebo-controlled
- Randomized
- Placebo-controlled
Primary result
mGFR · Week 13
Difference
−7.9 mL/min
95% CI −11.1 to −4.7
P < 0.001
Empagliflozinvs Placebo
difference −7.9 mL/min (95% CI −11.1 to −4.7); P < 0.001
As reported in the abstract
Further findings
| Outcome | Difference (mL) (95% CI) | P value | |
|---|---|---|---|
| Estimated ECV · Week 13 | −192.5 (−318.0 to −66.9) | P = 0.003 | |
| Estimated plasma volume (PV) · Week 13 | −128.9 (−218.0 to 39.8) | P = 0.005 | |
| −400−2000200Difference, mL (linear scale) |
Original publication
The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes. Diabetes Obes Metab. Published 3 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →